Anupam Rasayan India Ltd logo

Anupam Rasayan India Ltd

ANURAS NSE

Anupam Rasayan India Ltd is engaged in manufacturing of specialty chemicals, which are sold in local as well as exported to other countries.[1]

AI Verdict: HOLD Confidence: 4%

Anupam Rasayan shows strong TTM sales growth of 65% and profit growth of 82%, but trades at a steep PE of 65.7x with a low 3-year ROE of just 5%. The sharply divided analyst opinion (50% buy, 50% sell) reflects genuine uncertainty about whether the recent growth surge justifies the premium valuation.

Key Fundamentals

SmallcapSpecialty ChemicalsChemicals
Market Cap
₹14,517 Cr
Volatility
Moderate
P/E Ratio
84.67
EBITDA
₹525 Cr
Return on Equity
8.65%
Debt to Equity
0.44
Book Value
₹290.02
EPS
₹8.55
52W High
₹1,415
52W Low
₹1,045.2

Technical Indicators

Key Insights

Strengths

1
  • Company is expected to give good quarter

Weaknesses

4
  • Stock is trading at 4.37 times its book value
  • Tax rate seems low
  • Company has a low return on equity of 4.60% over last 3 years.
  • Dividend payout has been low at 9.85% of profits over last 3 years

Growth Rate

Revenue Growth
63.30% ↗
Net Income Growth
27.02% ↗
Cash Flow Change
-151.04% ↘
ROE
-9.11% ↘
ROCE
-11.11% ↘
EBITDA Margin (Avg.)
-22.66% ↘

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 1d ago
HOLD
Risk high

Anupam Rasayan shows strong TTM sales growth of 65% and profit growth of 82%, but trades at a steep PE of 65.7x with a low 3-year ROE of just 5%. The sharply divided analyst opinion (50% buy, 50% sell) reflects genuine uncertainty about whether the recent growth surge justifies the premium valuation.

Bull Case 7
  • TTM revenue growth of 65% signals a strong demand acceleration in specialty chemicals
  • TTM profit growth of 82% demonstrates significant operating leverage kicking in
  • 5-year compounded sales CAGR of 24% reflects a consistent long-term growth trajectory
  • 5-year compounded profit CAGR of 19% shows the company can convert top-line growth into earnings
  • Market cap of Rs 14,707 Cr provides reasonable scale and liquidity for institutional investors
  • Company is expected to deliver a good upcoming quarter per known screening parameters
  • 5-year stock CAGR of 11% shows the market has rewarded the business over medium term
Bear Case 8
  • PE ratio of 65.7x is excessively rich for a specialty chemicals company with single-digit ROE
  • 3-year ROE of only 5% indicates poor capital efficiency despite revenue growth
  • Price-to-book of 4.42x is elevated given the low return on equity of 4.60% over 3 years
  • 3-year compounded profit CAGR of -2% shows recent TTM surge is not yet a sustained trend
  • Dividend yield of just 0.06% with payout of only 9.85% of profits offers no income support
  • 50% of analysts rate the stock a Sell, reflecting significant institutional skepticism
  • 3-year stock CAGR of only 7% suggests prolonged periods of market underperformance
  • Low tax rate flagged as a concern — any normalization could compress earnings materially

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 14h ago
Positives 2
  • World-first ETFA via flow chemistry Jun 12

    Anupam Rasayan became the world's first company to commercialise ETFA using flow chemistry, reinforcing its position as a global innovator in specialty chemical production.

  • No new promoter share pledges Jun 9

    Promoters disclosed existing pledges for FY26 with no new encumbrances created during the year ended March 31, 2026, signalling stable promoter confidence.

Neutral 2
  • Open offer for Bliss GVS Pharma Jun 9

    Anupam Rasayan filed a Draft Letter of Offer to acquire up to 2,77,26,848 shares (26% of expanded capital) of Bliss GVS Pharma at ₹299 per share via a mandatory open offer.

  • Investor meeting at Jhagadia plant Jun 4

    Company scheduled an investor meeting at its Jhagadia GIDC Plant on June 9, 2026, hosted by Prabhudas Liladhar.

TL;DR: Anupam Rasayan is demonstrating strong innovation leadership with a world-first commercialisation of ETFA via flow chemistry, and promoter pledge stability adds comfort. The Bliss GVS Pharma open offer introduces a pharma diversification angle whose impact remains to be seen. No visible headwinds in recent news; the trend leans constructive if execution on new technology and the acquisition progresses smoothly.

Quarterly Results

  Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales
480
386
392
296
401
254
294
390
500
486
731
512
636
Expenses
363
285
285
216
308
201
214
266
356
362
596
385
498
Operating Profit
117
101
107
79
93
53
80
124
144
124
136
127
137
OPM %
24%
26%
27%
27%
23%
21%
27%
32%
29%
26%
19%
25%
22%
Other Income
24
12
3
2
12
6
2
-4
6
5
8
2
3
Interest
20
18
20
25
26
22
27
32
31
36
36
35
42
Depreciation
19
19
20
20
21
21
22
29
31
31
32
34
43
PBT
103
77
71
36
58
16
34
59
88
63
76
60
56
Tax %
29%
32%
31%
28%
30%
25%
10%
9%
29%
23%
24%
-1%
0%
Net Profit
73
52
49
26
40
12
31
54
63
48
57
61
56
EPS in Rs
5.27
3.59
3.78
1.68
2.82
0.36
1.52
2.56
4.05
3.1
3.9
4.31
3.75
Figures in ₹ Crores

Profit & Loss

  Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales
502
529
811
1,074
1,602
1,475
1,437
2,365
Expenses
408
394
617
769
1,171
1,094
1,036
1,841
Operating Profit
93
135
194
305
431
381
401
525
OPM %
19%
25%
24%
28%
27%
26%
28%
22%
Other Income
19
11
26
8
10
30
11
18
Interest
24
45
69
31
63
89
112
149
Depreciation
23
29
52
60
71
80
102
140
PBT
66
72
100
222
308
242
198
254
Tax %
24%
26%
30%
31%
30%
31%
19%
13%
Net Profit
49
53
70
152
217
167
160
222
EPS in Rs
9.85
10.64
7.04
15.18
16.83
11.71
8.49
14.94
Div. Payout %
0%
0%
7%
7%
15%
11%
9%
10%
Figures in ₹ Crores

Balance Sheet

  Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
50
50
100
100
107
110
110
146
Reserves
432
515
1,473
1,627
2,265
2,651
2,740
3,188
Borrowings
694
847
423
836
822
1,069
1,373
1,867
Other Liabilities
146
252
301
327
584
772
1,045
2,811
Total Liabilities
1,323
1,664
2,298
2,891
3,778
4,602
5,269
8,013
Fixed Assets
681
977
1,115
1,202
1,417
1,501
2,185
3,713
CWIP
191
101
43
44
120
609
216
114
Investments
0
0
0
149
67
67
9
19
Other Assets
451
586
1,140
1,496
2,173
2,424
2,860
4,167
Total Assets
1,323
1,664
2,298
2,891
3,778
4,602
5,269
8,013
Figures in ₹ Crores

Cash Flow

  Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
39
95
1
-171
292
59
-30
334
Investing
-250
-178
-193
-412
-523
-392
-330
-820
Financing
206
102
416
384
371
395
223
621
Net Cash Flow
-6
19
224
-199
140
62
-137
135
Free Cash Flow
-209
-85
-144
-318
232
-644
-440
-220
CFO/OP
55
77
10
-44
84
28
3
72
Figures in ₹ Crores

Ratios

  Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
88
89
92
95
95
143
186
148
Inventory Days
277
515
530
852
483
627
876
490
Days Payable
105
226
215
225
167
247
348
261
Cash Conversion Cycle
260
379
408
722
410
524
715
377
Working Capital Days
56
21
168
218
153
138
160
111
ROCE %
—
9%
10%
11%
13%
9%
7%
7%

Shareholding Pattern

As of Mar 2026
Promoters 59.07%
Public 23.93%
Others 9.74%
FIIs 6.91%
DIIs 0.35%
Total 100.00%
  Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Jul 2025Sep 2025Dec 2025Mar 2026
Promoters
65.40%
65.40%
65.40%
65.40%
65.18%
65.17%
65.16%
60.96%
60.81%
60.77%
60.73%
61.41%
61.26%
61.23%
61.23%
61.18%
61.18%
61.18%
59.07%
59.07%
59.07%
59.07%
FIIs
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
9.13%
8.07%
7.14%
7.01%
7.45%
6.46%
4.94%
0.00%
7.63%
7.60%
6.91%
DIIs
1.44%
2.00%
2.72%
3.15%
3.09%
3.95%
4.32%
6.19%
4.99%
3.74%
1.51%
2.51%
2.56%
2.65%
2.30%
2.32%
2.25%
2.24%
1.88%
1.37%
0.42%
0.35%
Government
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
Public
25.62%
23.71%
23.39%
22.73%
23.57%
24.05%
4.55%
4.69%
6.25%
5.90%
6.88%
24.37%
24.39%
25.94%
26.48%
26.23%
27.58%
25.54%
25.20%
24.89%
24.78%
23.93%
Others
7.55%
8.90%
8.50%
8.72%
8.16%
6.83%
25.97%
28.17%
27.95%
29.59%
30.88%
2.58%
3.72%
3.04%
2.98%
2.82%
2.53%
6.11%
13.84%
7.03%
8.12%
9.74%
No. of Shareholders
0
57
77,371
71,454
60,629
65,071
65,870
71,492
66,507
61,504
61,129
60,089
57,623
62,218
63,866
60,938
57,478
47,711
48,524
48,785
47,469
43,475

Documents

Frequently Asked Questions about Anupam Rasayan India Ltd

What does Anupam Rasayan India Ltd do?
Anupam Rasayan India Ltd is engaged in manufacturing of specialty chemicals, which are sold in local as well as exported to other countries.[1]
Where is Anupam Rasayan India Ltd (ANURAS) listed?
Anupam Rasayan India Ltd is listed on the Indian stock exchanges. It is listed on NSE: ANURAS and BSE: 543275. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Anupam Rasayan India Ltd belong to?
Anupam Rasayan India Ltd operates in the Commodities sector within the Chemicals & Petrochemicals industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Anupam Rasayan India Ltd?
Anupam Rasayan India Ltd has a market capitalisation of approximately ₹14516.80 Cr. Based on this, it is classified as a Mid Cap stock.
What is the PE ratio of Anupam Rasayan India Ltd?
The Price-to-Earnings (PE) ratio of Anupam Rasayan India Ltd is 84.67. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Anupam Rasayan India Ltd?
Over the past 52 weeks, Anupam Rasayan India Ltd has traded between a low of ₹1,045.2 and a high of ₹1,415. This range helps investors understand the stock's price volatility and recent trading levels.
Does Anupam Rasayan India Ltd pay dividends?
Yes, Anupam Rasayan India Ltd has a dividend yield of 0.06%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of Anupam Rasayan India Ltd?
Anupam Rasayan India Ltd has a Return on Equity (ROE) of 8.65%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Anupam Rasayan India Ltd on Tapetide?
On Tapetide, you can view Anupam Rasayan India Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.

Company Information

Anupam Rasayan India Ltd is engaged in manufacturing of specialty chemicals, which are sold in local as well as exported to other countries.[1]

Website anupamrasayan.com
CEO Mr. Gopal Puranmal Agrawal
Employees 2,606
Listed 2021-03-24
Face Value ₹ 10
Issued Size 11,38,48,310

Explore More

More in Commodities → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List